April 1 - 5, 2025 | Vienna, Austria
Taconic Biosciences is excited to attend AD/PD 2025, where leaders in the field will gather to explore groundbreaking research and innovative treatments for Alzheimer's and Parkinson's Disease.
Are you attending this year's international conference on Alzheimer's and Parkinson's Disease and related neurological disorders? We'd love to meet with you! Stop by our scientific poster to learn more about the latest advancements in translational mouse models of Alzheimer's and Parkinson's disease, or complete the form below to request a meeting to discuss your research needs.
Thursday, April 3, 2025 | 4:20 PM - 5:20 PM | Hall A
Symposium Title: Latest Advancements in Translational Mouse Models of Alzheimer’s Disease, Tauopathies & Parkinson’s Disease
Presentation Title: A new amyloid-beta and tau co-pathology mouse model of Alzheimer's disease
Join Drs. Laura Griffin and Anastasia Noël as they present innovative in vivo and ex vivo data on cutting-edge models of tau pathology and amyloid-beta/tau co-pathology. Learn how these models translate to human Alzheimer’s disease and other tauopathies.
An interactive Q&A session will follow, offering a unique opportunity to engage directly with the experts. Don’t miss out on the latest breakthroughs in clinically relevant and translational disease models.
Biospective in collaboration with Taconic Biosciences
1st Showing: Wednesday, April 2 - 8:00 AM - 10:00 AM
2nd Showing: Thursday, April 3 - 5:30 PM - 6:30 PM
Poster Board #2898: 3D Whole-Brain Imaging of Parenchymal/Vascular Amyloid Plaque Architecture During Disease Progression in a Transgenic Mouse Model of Alzheimer's Disease
This study uses high-throughput light sheet fluorescence microscopy and AI-driven image analysis to map age- and sex-dependent amyloid plaque accumulation in a transgenic mouse model of Alzheimer’s disease. Findings highlight faster amyloidosis progression in female mice and delayed vascular plaque deposition, underscoring the importance of considering sex and age in preclinical drug evaluation.
Gubra in collaboration with Taconic Biosciences
1st Session: Wednesday, April 2 - 10:30 AM - 11:30 AM
2nd Session: Friday, April 4 - 3:00 PM - 4:00 PM
3rd Session: Saturday, April 5 - 10:00 AM - 11:00 AM
Join Taconic Biosciences and Transpharmation at AD/PD for an exclusive collaboration highlighting the latest advancements in Alzheimer's disease mouse models and drug development research. Stop by Transpharmation's table during office hours to connect with experts and explore innovative research solutions.
Field Applications Scientist
Dr. Laura Griffin has been working with preclinical models for a decade and is experienced in choosing appropriate models for various research applications. She obtained her PhD in Food Science and Technology at Virginia Tech, where she focused on the mechanisms by which dietary bioactive compounds influence the onset of metabolic syndrome using preclinical models. As a postdoctoral fellow at the Plants for Human Health Institute, her research shifted to focus on the impact of the gut microbiome on the metabolism of bioactive compounds. In addition to her expertise in metabolic diseases in preclinical models, Dr. Griffin is also versed in laboratory animal diets and their usage in preclinical applications.
Research Scientist
Anastasia Noël, Ph.D. is an accomplished Research Scientist with over 10 years of extensive experience in research project management. She specializes in overseeing and conducting preclinical and laboratory-related studies, serving as a Study Director for various projects. Anastasia possesses a strong background in neurobiology, particularly in areas such as Alzheimer's disease, traumatic brain injury (TBI), and neurodegeneration. Her expertise encompasses designing and executing comprehensive animal model studies, where she effectively manages project timelines, performs rigorous data analysis, and prepares detailed reports. Anastasia is skilled in a multitude of research techniques including cell culture, behavioral studies, histopathology, molecular biology, and biochemical analyses. She has a proven track record in team management, successfully leading personnel with diverse educational backgrounds to achieve research objectives. Anastasia earned her Ph.D. in neurobiology from Université de Poitiers in 2013, followed by two post-doctoral training experiences focused on neurodegeneration at Laval University and McGill University from 2013 to 2018. Her professional journey continued as a Research Associate at McGill University and progressed to her current roles as Research Scientist at Biospective.